Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 9, 2013, Pages 1091-1099

  Patel, Anant R C ^a   Kowlessar, Beverly S ^a   Donaldson, Gavin C ^a   Mackay, Alex J ^a   Singh, Richa ^a   George, Siobhan N ^a   Garcha, Davinder S ^a   Wedzicha, Jadwiga A ^a   Hurst, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arterial stiffness; Brain natriuretic peptide; Chronic obstructive pulmonary disease; Exacerbation; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; TROPONIN T;

AGED; AORTA; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HEART MUSCLE INJURY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS;

AGED; AGED, 80 AND OVER; AORTA; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; HEART RATE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULSE WAVE ANALYSIS; RISK FACTORS; SPIROMETRY; SPUTUM; TROPONIN T; VASCULAR STIFFNESS;

EID: 84887314561     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201306-1170OC     Document Type: Article

References (48)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. GOLD - the Global initiative for chronic Obstructive Lung Disease [updated 2013 Feb 1; accessed 2013 Jun 20]. Availablefrom:http://www.goldcopd. org/guidelines-global-strategy-for-diagnosis-management.html.
3. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969.
4. Soler-Cataluñ a JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60: 925-931.
5. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-796.
6. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
7. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
8. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
9. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
10. Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012;141:851-857.
11. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-2011.
12. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008;29:96-103.
13. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-1097.
14. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor J, McAlpine L, Chalmers G, Newby DE, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012;39:1097-1103.
15. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-768.
16. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769-774.
17. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, Gorkiewicz-Kot I, Tracz W. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009;102: 1176-1182.
18. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215.
19. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327.
20. Mitchell GF, Hwang S-J, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation 2010;121:505- 511.
21. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, Breen L, Wilkinson IB, McEniery CM, Donaldson K, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008;63:306- 311.
22. Patel ARC, Donaldson GC, Kowlessar BS, Mackay AJ, Garcha DS, George SN, Wedzicha JA, Hurst JR. The impact of airway infection on cardiovascular risk during COPD exacerbations.Eur Respir J 2012;40:395s.
23. Patel ARC, Kowlessar BS, Mackay AJ, Donaldson GC, Wedzicha JA, Hurst JR. Relationships between COPD exacerbation frequency and arterial stiffness. Am J Respir Crit Care Med 2012;185:A5854.
24. Patel ARC, Kowlessar BS, Mackay AJ, Donaldson GC, Wedzicha JA, Hurst JR. The time-course of changes in arterial stiffness during COPD exacerbations. Am J Respir Crit Care Med 2012;185:A5853.
25. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605.
26. Garcha DS, Thurston SJ, Patel ARC, Mackay AJ, Goldring JJ, Donaldson GC, McHugh TD, Wedzicha JA. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67:1075-1080.
27. Quint JK, Donaldson GC, Goldring JJP, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010;137:812-822.
28. Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011;66:775-781.
29. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, Mueller B, Tamm M, Mueller C. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133: 1088-1094.
30. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-1265.
31. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:1208-1214.
32. Maclay JD, McAllister DA, Rabinovich R, Haq I, Maxwell S, Hartland S, Connell M, Murchison JT, van Beek EJ, Gray RD, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012;67:606-612.
33. Vlachopoulos C, Alexopoulos N, Stefanadis C. Fast in the aorta, slow in the coronaries. Cardiology 2010;116:257-260.
34. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, Macnee W. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:513-520.
35. Marchetti N, Ciccolella DE, Jacobs MR, Crookshank A, Gaughan JP, Kashem MA, Bove AA, Criner GJ. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD 2011;8:60-65.
36. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994-999.
37. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, Toutouza M, Stefanadis C. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005;112:2193-2200.
38. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, Vallance P. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002; 105:2600-2604.
39. Wallace SML, Mäki-Petäjä KM, Cheriyan J, Davidson EH, Cherry L, McEniery CM, Sattar N, Wilkinson IB, Kharbanda RK. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol 2010;70:799-806.
40. The effect of statins in patients with chronic obstructive pulmonary disease (COPD) [updated 2013 Apr 18; accessed 2013 Jun 20]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01151306.
41. Dransfield MT, Cockcroft JR, Townsend RR, Coxson HO, Sharma SS, Rubin DB, Emmett AH, Cicale MJ, Crater GD, Martinez FJ. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med 2011;105:1322-1330.
42. Effects of roflumilast on subclinical atherosclerosis in chronic obstructive pulmonary disease (COPD) [updated 2012 Jun 27; accessed 2013 Jun 20]. Availablefromhttp://www.clinicaltrials.gov/ct2/show/NCT01630200.
43. Effect of roflumilast at acute exacerbations of chronic obstructive pulmonary disease [updated 2013 Jan 4; accessed 2013 Jun 20]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01473758.
44. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-1079.
45. Lahousse L, van den Bouwhuijsen QJA, Loth DW, Joos GF, Hofman A, Witteman JC, van der Lugt A, Brusselle GG, Stricker BH. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: The Rotterdam Study. Am J Respir Crit Care Med 2013; 187:58-64.
46. Bazaz R, Marriott HM, Francis SE, Dockrell DH. Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J Infect 2013;66:1-17.
47. Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR, Shale DJ, Bolton CE. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros 2012;12:125-129.
48. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-1192.